Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA(2) and cardiovascular diseases

C. Ballantyne; M. Cushman; B. Psaty; C. Furberg; K. T. Khaw; M. Sandhu; J. Oldgren; G. P. Rossi; G. Maiolino; M. Cesari; L. Lenzini; S. K. James; E. Rimm; R. Collins; J. Anderson; W. Koenig; H. Brenner; D. Rothenbacher; Göran Berglund; M. Persson; P. Berger; E. Brilakis; J. P. McConnell; W. Koenig; R. Sacco; M. Elkind; P. Talmud; E. Rimm; C. P. Cannon; C. Packard; C. P. Cannon; E. Barrett-Connor; A. Hofman; I. Kardys; J. C. M. Witteman; M. Criqui; J. P. Corsetti; D. L. Rainwater; A. J. Moss; S. Robins; H. Bloomfield; D. Collins; C. Packard; P. Ridker; C. Ballantyne; C. P. Cannon; R. Collins; M. Criqui; M. Cushman; J. Danesh; D. Gu; A. Hofman; J. J. Nelson; C. Packard; S. Thompson; A. Zalewski; J. Danesh; R. Collins; E. Di Angelantonio; S. Kaptoge; A. Thompson; S. Thompson; S. Watson; A. Wood

Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA(2) and cardiovascular diseases

C. Ballantyne, M. Cushman, B. Psaty, C. Furberg, K. T. Khaw, M. Sandhu, J. Oldgren, G. P. Rossi, G. Maiolino, M. Cesari, L. Lenzini, S. K. James, E. Rimm, R. Collins, J. Anderson, W. Koenig, H. Brenner, D. Rothenbacher, Göran Berglund, M. PerssonP. Berger, E. Brilakis, J. P. McConnell, W. Koenig, R. Sacco, M. Elkind, P. Talmud, E. Rimm, C. P. Cannon, C. Packard, C. P. Cannon, E. Barrett-Connor, A. Hofman, I. Kardys, J. C. M. Witteman, M. Criqui, J. P. Corsetti, D. L. Rainwater, A. J. Moss, S. Robins, H. Bloomfield, D. Collins, C. Packard, P. Ridker, C. Ballantyne, C. P. Cannon, R. Collins, M. Criqui, M. Cushman, J. Danesh, D. Gu, A. Hofman, J. J. Nelson, C. Packard, S. Thompson, A. Zalewski, J. Danesh, R. Collins, E. Di Angelantonio, S. Kaptoge, A. Thompson, S. Thompson, S. Watson, A. Wood

Internal Medicine - Epidemiology

Research output: Contribution to journal › Review article › peer-review

Abstract

Background A large number of observational epidemiological studies have reported generally positive associations' between circulating mass and activity levels of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and the risk of cardiovascular diseases. Few studies have been large enough to provide reliable estimates in different circumstances, such as in different subgroups (e.g., by age group, sex, or smoking status) or at different Lp-PLA2 levels. Moreover, most published studies have related disease risk only to baseline values of Lp-PLA(2) markers (which can lead to substantial underestimation of any risk relationships because of within-person variability over time) and have used different approaches to adjustment for possible confounding factors. Objectives By combination of data from individual participants from all relevant observational studies in a systematic,meta-analysis, with correction for regression dilution (using available data on serial measurements of Lp-PLA(2)), the Lp-PLA(2) Studies Collaboration will aim to characterize more precisely than has previously been possible the strength and shape of the age and sex-specific associations of plasma Lp-PLA(2) with coronary heart disease (and, where data are sufficient with other vascular diseases, such as ischaemic stroke). It will also help to determine to what extent such associations are independent of possible confounding factors and to explore potential sources of heterogeneity among studies, such as those related to assay methods and study design. It is anticipated that the present collaboration will serve as a framework to investigate related questions on Lp-PLA(2) and cardiovascular outcomes. Methods A central database is being established containing data on circulating Lp-PLA(2) values, sex and other potential confounding factors, age at baseline Lp-PLA(2) Measurement, age at event or at last follow-up, major vascular morbidity and cause-specific mortality. Information about any repeat measurements of Lp-PLA2 and potential confounding factors has been sought to allow adjustment for possible confounding and correction for regression dilution. The analyses will involve age-specific regression models. Synthesis of the available observational studies of Lp-PLA(2) will yield information on a total of about 15 000 cardiovascular disease endpoints.

Original language	English
Pages (from-to)	41344
Journal	European Journal of Cardiovascular Prevention & Rehabilitation
Volume	14
Issue number	1
Publication status	Published - 2007

Subject classification (UKÄ)

Other Clinical Medicine

Free keywords

vascular
disease
meta-analysis
lipoprotein-associated phospholipase A(2)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Ballantyne, C., Cushman, M., Psaty, B., Furberg, C., Khaw, K. T., Sandhu, M., Oldgren, J., Rossi, G. P., Maiolino, G., Cesari, M., Lenzini, L., James, S. K., Rimm, E., Collins, R., Anderson, J., Koenig, W., Brenner, H., Rothenbacher, D., Berglund, G., ... Wood, A. (2007). Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA(2) and cardiovascular diseases. European Journal of Cardiovascular Prevention & Rehabilitation, 14(1), 41344.

@article{9600767181d6459c966e2611ac2d30b3,

title = "Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA(2) and cardiovascular diseases",

abstract = "Background A large number of observational epidemiological studies have reported generally positive associations' between circulating mass and activity levels of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and the risk of cardiovascular diseases. Few studies have been large enough to provide reliable estimates in different circumstances, such as in different subgroups (e.g., by age group, sex, or smoking status) or at different Lp-PLA2 levels. Moreover, most published studies have related disease risk only to baseline values of Lp-PLA(2) markers (which can lead to substantial underestimation of any risk relationships because of within-person variability over time) and have used different approaches to adjustment for possible confounding factors. Objectives By combination of data from individual participants from all relevant observational studies in a systematic,meta-analysis, with correction for regression dilution (using available data on serial measurements of Lp-PLA(2)), the Lp-PLA(2) Studies Collaboration will aim to characterize more precisely than has previously been possible the strength and shape of the age and sex-specific associations of plasma Lp-PLA(2) with coronary heart disease (and, where data are sufficient with other vascular diseases, such as ischaemic stroke). It will also help to determine to what extent such associations are independent of possible confounding factors and to explore potential sources of heterogeneity among studies, such as those related to assay methods and study design. It is anticipated that the present collaboration will serve as a framework to investigate related questions on Lp-PLA(2) and cardiovascular outcomes. Methods A central database is being established containing data on circulating Lp-PLA(2) values, sex and other potential confounding factors, age at baseline Lp-PLA(2) Measurement, age at event or at last follow-up, major vascular morbidity and cause-specific mortality. Information about any repeat measurements of Lp-PLA2 and potential confounding factors has been sought to allow adjustment for possible confounding and correction for regression dilution. The analyses will involve age-specific regression models. Synthesis of the available observational studies of Lp-PLA(2) will yield information on a total of about 15 000 cardiovascular disease endpoints.",

keywords = "vascular, disease, meta-analysis, lipoprotein-associated phospholipase A(2)",

author = "C. Ballantyne and M. Cushman and B. Psaty and C. Furberg and Khaw, \{K. T.\} and M. Sandhu and J. Oldgren and Rossi, \{G. P.\} and G. Maiolino and M. Cesari and L. Lenzini and James, \{S. K.\} and E. Rimm and R. Collins and J. Anderson and W. Koenig and H. Brenner and D. Rothenbacher and G{\"o}ran Berglund and M. Persson and P. Berger and E. Brilakis and McConnell, \{J. P.\} and W. Koenig and R. Sacco and M. Elkind and P. Talmud and E. Rimm and Cannon, \{C. P.\} and C. Packard and Cannon, \{C. P.\} and E. Barrett-Connor and A. Hofman and I. Kardys and Witteman, \{J. C. M.\} and M. Criqui and Corsetti, \{J. P.\} and Rainwater, \{D. L.\} and Moss, \{A. J.\} and S. Robins and H. Bloomfield and D. Collins and C. Packard and P. Ridker and C. Ballantyne and Cannon, \{C. P.\} and R. Collins and M. Criqui and M. Cushman and J. Danesh and D. Gu and A. Hofman and Nelson, \{J. J.\} and C. Packard and S. Thompson and A. Zalewski and J. Danesh and R. Collins and \{Di Angelantonio\}, E. and S. Kaptoge and A. Thompson and S. Thompson and S. Watson and A. Wood",

year = "2007",

language = "English",

volume = "14",

pages = "41344",

journal = "European Journal of Cardiovascular Prevention \& Rehabilitation",

issn = "1741-8275",

publisher = "Lippincott Williams \& Wilkins",

number = "1",

}

Ballantyne, C, Cushman, M, Psaty, B, Furberg, C, Khaw, KT, Sandhu, M, Oldgren, J, Rossi, GP, Maiolino, G, Cesari, M, Lenzini, L, James, SK, Rimm, E, Collins, R, Anderson, J, Koenig, W, Brenner, H, Rothenbacher, D, Berglund, G, Persson, M, Berger, P, Brilakis, E, McConnell, JP, Koenig, W, Sacco, R, Elkind, M, Talmud, P, Rimm, E, Cannon, CP, Packard, C, Cannon, CP, Barrett-Connor, E, Hofman, A, Kardys, I, Witteman, JCM, Criqui, M, Corsetti, JP, Rainwater, DL, Moss, AJ, Robins, S, Bloomfield, H, Collins, D, Packard, C, Ridker, P, Ballantyne, C, Cannon, CP, Collins, R, Criqui, M, Cushman, M, Danesh, J, Gu, D, Hofman, A, Nelson, JJ, Packard, C, Thompson, S, Zalewski, A, Danesh, J, Collins, R, Di Angelantonio, E, Kaptoge, S, Thompson, A, Thompson, S, Watson, S & Wood, A 2007, 'Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA(2) and cardiovascular diseases', European Journal of Cardiovascular Prevention & Rehabilitation, vol. 14, no. 1, pp. 41344.

TY - JOUR

T1 - Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA(2) and cardiovascular diseases

AU - Ballantyne, C.

AU - Cushman, M.

AU - Psaty, B.

AU - Furberg, C.

AU - Khaw, K. T.

AU - Sandhu, M.

AU - Oldgren, J.

AU - Rossi, G. P.

AU - Maiolino, G.

AU - Cesari, M.

AU - Lenzini, L.

AU - James, S. K.

AU - Rimm, E.

AU - Collins, R.

AU - Anderson, J.

AU - Koenig, W.

AU - Brenner, H.

AU - Rothenbacher, D.

AU - Berglund, Göran

AU - Persson, M.

AU - Berger, P.

AU - Brilakis, E.

AU - McConnell, J. P.

AU - Koenig, W.

AU - Sacco, R.

AU - Elkind, M.

AU - Talmud, P.

AU - Rimm, E.

AU - Cannon, C. P.

AU - Packard, C.

AU - Cannon, C. P.

AU - Barrett-Connor, E.

AU - Hofman, A.

AU - Kardys, I.

AU - Witteman, J. C. M.

AU - Criqui, M.

AU - Corsetti, J. P.

AU - Rainwater, D. L.

AU - Moss, A. J.

AU - Robins, S.

AU - Bloomfield, H.

AU - Collins, D.

AU - Packard, C.

AU - Ridker, P.

AU - Ballantyne, C.

AU - Cannon, C. P.

AU - Collins, R.

AU - Criqui, M.

AU - Cushman, M.

AU - Danesh, J.

AU - Gu, D.

AU - Hofman, A.

AU - Nelson, J. J.

AU - Packard, C.

AU - Thompson, S.

AU - Zalewski, A.

AU - Danesh, J.

AU - Collins, R.

AU - Di Angelantonio, E.

AU - Kaptoge, S.

AU - Thompson, A.

AU - Thompson, S.

AU - Watson, S.

AU - Wood, A.

PY - 2007

Y1 - 2007

N2 - Background A large number of observational epidemiological studies have reported generally positive associations' between circulating mass and activity levels of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and the risk of cardiovascular diseases. Few studies have been large enough to provide reliable estimates in different circumstances, such as in different subgroups (e.g., by age group, sex, or smoking status) or at different Lp-PLA2 levels. Moreover, most published studies have related disease risk only to baseline values of Lp-PLA(2) markers (which can lead to substantial underestimation of any risk relationships because of within-person variability over time) and have used different approaches to adjustment for possible confounding factors. Objectives By combination of data from individual participants from all relevant observational studies in a systematic,meta-analysis, with correction for regression dilution (using available data on serial measurements of Lp-PLA(2)), the Lp-PLA(2) Studies Collaboration will aim to characterize more precisely than has previously been possible the strength and shape of the age and sex-specific associations of plasma Lp-PLA(2) with coronary heart disease (and, where data are sufficient with other vascular diseases, such as ischaemic stroke). It will also help to determine to what extent such associations are independent of possible confounding factors and to explore potential sources of heterogeneity among studies, such as those related to assay methods and study design. It is anticipated that the present collaboration will serve as a framework to investigate related questions on Lp-PLA(2) and cardiovascular outcomes. Methods A central database is being established containing data on circulating Lp-PLA(2) values, sex and other potential confounding factors, age at baseline Lp-PLA(2) Measurement, age at event or at last follow-up, major vascular morbidity and cause-specific mortality. Information about any repeat measurements of Lp-PLA2 and potential confounding factors has been sought to allow adjustment for possible confounding and correction for regression dilution. The analyses will involve age-specific regression models. Synthesis of the available observational studies of Lp-PLA(2) will yield information on a total of about 15 000 cardiovascular disease endpoints.

AB - Background A large number of observational epidemiological studies have reported generally positive associations' between circulating mass and activity levels of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and the risk of cardiovascular diseases. Few studies have been large enough to provide reliable estimates in different circumstances, such as in different subgroups (e.g., by age group, sex, or smoking status) or at different Lp-PLA2 levels. Moreover, most published studies have related disease risk only to baseline values of Lp-PLA(2) markers (which can lead to substantial underestimation of any risk relationships because of within-person variability over time) and have used different approaches to adjustment for possible confounding factors. Objectives By combination of data from individual participants from all relevant observational studies in a systematic,meta-analysis, with correction for regression dilution (using available data on serial measurements of Lp-PLA(2)), the Lp-PLA(2) Studies Collaboration will aim to characterize more precisely than has previously been possible the strength and shape of the age and sex-specific associations of plasma Lp-PLA(2) with coronary heart disease (and, where data are sufficient with other vascular diseases, such as ischaemic stroke). It will also help to determine to what extent such associations are independent of possible confounding factors and to explore potential sources of heterogeneity among studies, such as those related to assay methods and study design. It is anticipated that the present collaboration will serve as a framework to investigate related questions on Lp-PLA(2) and cardiovascular outcomes. Methods A central database is being established containing data on circulating Lp-PLA(2) values, sex and other potential confounding factors, age at baseline Lp-PLA(2) Measurement, age at event or at last follow-up, major vascular morbidity and cause-specific mortality. Information about any repeat measurements of Lp-PLA2 and potential confounding factors has been sought to allow adjustment for possible confounding and correction for regression dilution. The analyses will involve age-specific regression models. Synthesis of the available observational studies of Lp-PLA(2) will yield information on a total of about 15 000 cardiovascular disease endpoints.

KW - vascular

KW - disease

KW - meta-analysis

KW - lipoprotein-associated phospholipase A(2)

M3 - Review article

SN - 1741-8275

VL - 14

SP - 41344

JO - European Journal of Cardiovascular Prevention & Rehabilitation

JF - European Journal of Cardiovascular Prevention & Rehabilitation

IS - 1

ER -

Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA(2) and cardiovascular diseases

Abstract

Subject classification (UKÄ)

Free keywords

UN SDGs

Fingerprint

Cite this